BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11499806)

  • 1. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.
    Wu RS; Kobie JJ; Besselsen DG; Fong TC; Mack VD; McEarchern JA; Akporiaye ET
    Cancer Immunol Immunother; 2001 Jul; 50(5):229-40. PubMed ID: 11499806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon gamma and antisense transforming growth factor beta transgenes synergize to enhance the immunogenicity of a murine mammary carcinoma.
    McEarchern JA; Besselsen DG; Akporiaye ET
    Cancer Immunol Immunother; 1999; 48(2-3):63-70. PubMed ID: 10414459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells.
    Park JA; Wang E; Kurt RA; Schluter SF; Hersh EM; Akporiaye ET
    Cancer Gene Ther; 1997; 4(1):42-50. PubMed ID: 9012450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes.
    Qian HN; Liu GZ; Cao SJ; Feng J; Ye X
    Int J Gynecol Cancer; 2002; 12(1):80-5. PubMed ID: 11860540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma.
    Hurwitz AA; Townsend SE; Yu TF; Wallin JA; Allison JP
    Int J Cancer; 1998 Jul; 77(1):107-13. PubMed ID: 9639401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses.
    Zhang Y; Morgan R; Chen C; Cai Y; Clark E; Khan WN; Shin SU; Cho HM; Al Bayati A; Pimentel A; Rosenblatt JD
    Int Immunol; 2016 Sep; 28(9):423-33. PubMed ID: 26895637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.
    Pulaski BA; Smyth MJ; Ostrand-Rosenberg S
    Cancer Res; 2002 Aug; 62(15):4406-12. PubMed ID: 12154047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis.
    duPre' SA; Redelman D; Hunter KW
    Exp Mol Pathol; 2008 Dec; 85(3):174-88. PubMed ID: 18929358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
    Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
    Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells.
    Nanni P; De Giovanni C; Landuzzi L; Nicoletti G; Frabetti F; Rossi I; Cavallo F; Giovarelli M; Forni G; Lollini PL
    Br J Cancer; 1996 Nov; 74(10):1564-9. PubMed ID: 8932336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
    Hurwitz AA; Yu TF; Leach DR; Allison JP
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10067-71. PubMed ID: 9707601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-beta1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells.
    Banu N; Meyers CM
    Kidney Int; 1999 Sep; 56(3):985-94. PubMed ID: 10469366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.
    Chen X; Yang Y; Zhou Q; Weiss JM; Howard OZ; McPherson JM; Wakefield LM; Oppenheim JJ
    PLoS One; 2014; 9(1):e85398. PubMed ID: 24416401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
    Pulaski BA; Ostrand-Rosenberg S
    Cancer Res; 1998 Apr; 58(7):1486-93. PubMed ID: 9537252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions.
    Tzai TS; Shiau AL; Liu LL; Wu CL
    Anticancer Res; 2000; 20(3A):1557-62. PubMed ID: 10928070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.